brontictuzumab
PreclinicalMonoclonal antibody
brontictuzumab is one of 14 small molecule programs targeting Adenoid Cystic Carcinoma. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Adenoid Cystic Carcinoma
#DrugCompanyPhaseTrials
1Adriamycin
PfizerApproved
Afinitor
NovartisApproved
Lenvima
EisaiPhase 2
Ellence
PfizerPhase 2
Padcev
PfizerPhase 2
Rybrevant
Johnson & JohnsonPhase 2
Zanzalintinib
Merck & Co.Phase 2
Becotatug Vedotin
FFudan University
Phase 2
Verzenio
Eli LillyPreclinical
EGFR-TK Inhibitor
LLuBing
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for brontictuzumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Preclinical[1]
- Company
- OOncoMed Pharmaceuticals, Inc.